Login to Your Account

Clinic Roundup

Thursday, October 25, 2012

• Oncolytics Biotech Inc., of Calgary, Alberta, said it completed patient enrollment in its U.S. Phase II trial testing intravenous administration of oncolytic virus Reolysin in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription